Pharmaceutical Investing Agile Therapeutics Announces FDA Acceptance of the NDA Resubmission of Twirla®
Pharmaceutical Investing Agile Therapeutics Resubmits New Drug Application (NDA) for its Transdermal Low-Dose Contraceptive Patch,
AMENDED FROM SOURCE - Blue Sky Uranium Increases and Closes 2nd and Final Tranche of the Oversubscribed Non-Brokered Private Placement
